USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
JPS63203626A
(ja)
|
1987-02-19 |
1988-08-23 |
Ajinomoto Co Inc |
免疫抑制剤
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
ATE135397T1
(de)
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
JP2919890B2
(ja)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5891693A
(en)
|
1990-01-25 |
1999-04-06 |
Alusuisse Holdings A.G. |
Recombinant DNA methods vectors and host cells
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5639635A
(en)
|
1994-11-03 |
1997-06-17 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
WO1997038123A1
(en)
|
1996-04-05 |
1997-10-16 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
DE19751857A1
(de)
|
1997-11-22 |
1999-05-27 |
Kronos Titan Gmbh |
Phosphonatosiloxanbehandelte anorganische Partikel
|
WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP2261229A3
(en)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
JP2003512019A
(ja)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
変化したエフェクター機能を有するポリペプチド変異体
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
ATE422369T1
(de)
|
1999-12-24 |
2009-02-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DE10045592A1
(de)
*
|
2000-09-15 |
2002-03-28 |
Klaus Pfizenmaier |
Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CN101940189A
(zh)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
GB0100551D0
(en)
*
|
2001-01-09 |
2001-02-21 |
Queen Mary & Westfield College |
Protein
|
WO2002076489A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
WO2003085119A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
JP2006518583A
(ja)
*
|
2002-10-14 |
2006-08-17 |
エフ.ホフマン−ラ ロシュ アーゲー |
Il−15アンタゴニスト
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
JP2006520584A
(ja)
|
2002-11-08 |
2006-09-14 |
アブリンクス エン.ヴェー. |
安定化単一ドメイン抗体
|
PL212899B1
(pl)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
HUE031632T2
(en)
|
2003-11-05 |
2017-07-28 |
Roche Glycart Ag |
Antigen binding molecules with enhanced Fc receptor binding affinity and effector function
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
AU2005211725B2
(en)
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
MX2007015107A
(es)
|
2005-06-03 |
2008-02-15 |
Genentech Inc |
Metodo para producir anticuerpos con funcion mejorada.
|
WO2006135740A1
(en)
|
2005-06-10 |
2006-12-21 |
Albert Einstein College Of Medicine Of Yeshiva University |
Pegylated hemoglobin and albumin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
DK2173890T3
(da)
|
2007-06-21 |
2011-06-27 |
Univ Muenchen Tech |
Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
|
EP2527435B2
(en)
|
2007-07-12 |
2021-10-13 |
Sangamo BioSciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
|
US8592555B2
(en)
|
2008-08-11 |
2013-11-26 |
Emd Millipore Corporation |
Immunoglobulin-binding proteins with improved specificity
|
EP2398494A4
(en)
*
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
WO2011020047A1
(en)
|
2009-08-14 |
2011-02-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
CA2789810C
(en)
*
|
2010-02-17 |
2020-12-01 |
Csl Limited |
Compositions and methods for targeting type 1 interferon-producing cells
|
EP2553101A4
(en)
*
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
CYTOKINES ACTIVATED BY PROTEASES
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
BR112012029577B1
(pt)
|
2010-05-21 |
2022-04-12 |
Xl-Protein Gmbh |
Conjugado de fármaco compreendendo polipeptídeos helicoidais randômicos prolina/alanina biossintéticos, e composição farmacêutica ou diagnóstica
|
AU2011305476B2
(en)
|
2010-09-21 |
2016-12-01 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
US20130225496A1
(en)
|
2010-11-01 |
2013-08-29 |
Novozymes Biopharma Dk A/S |
Albumin Variants
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
LT2654780T
(lt)
|
2010-12-23 |
2017-03-27 |
Janssen Biotech, Inc. |
Aktyvūs proteazei atsparūs antikūnai - fc mutantai
|
JP5878182B2
(ja)
*
|
2011-02-10 |
2016-03-08 |
ロシュ グリクアート アーゲー |
ミュータントインターロイキン−2ポリペプチド
|
EP2819788B1
(en)
|
2012-02-27 |
2018-08-22 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
RU2015107891A
(ru)
|
2012-08-09 |
2016-09-27 |
Роше Гликарт Аг |
Антитела к asgpr и их применения
|
CA2882173C
(en)
|
2012-08-23 |
2020-08-04 |
Lee Tech Llc |
A method of and system for producing oil and valuable byproducts from grains in dry milling systems with a back-end dewater milling unit
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
US9926245B2
(en)
|
2013-09-30 |
2018-03-27 |
Pioneer Energy |
Fuels and chemicals from lower alkanes
|
MX2016008631A
(es)
|
2014-01-08 |
2016-12-20 |
Shanghai hengrui pharmaceutical co ltd |
Proteina heterodimérica il-5 y usos de la misma.
|
KR20170068553A
(ko)
|
2014-10-14 |
2017-06-19 |
아르모 바이오사이언시스 인코포레이티드 |
인터류킨-15 조성물 및 이의 용도
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
WO2016130451A1
(en)
|
2015-02-09 |
2016-08-18 |
Dnx Biotech, Llc |
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
JP2018509172A
(ja)
|
2015-03-27 |
2018-04-05 |
ザ ユニバーシティ オブ クィーンズランド |
タンパク質への非天然アミノ酸組込みのためのプラットフォーム
|
US20160362469A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
CA3023980A1
(en)
|
2016-05-16 |
2017-11-23 |
Checkmab S.R.L. |
Markers selectively deregulated in tumor-infiltrating regulatory t cells
|
WO2018071919A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
|
EP3733716A4
(en)
|
2017-12-26 |
2021-11-24 |
Nanjing GenScript Biotech Co., Ltd. |
DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
|
CN108218993B
(zh)
|
2018-01-05 |
2020-11-17 |
阿思科力(苏州)生物科技有限公司 |
一种以robo1为靶点的双特异性抗体及其制备和应用
|
TW201938196A
(zh)
|
2018-01-18 |
2019-10-01 |
美商南特生物科學股份有限公司 |
融合蛋白擴展
|
BR112020017016A2
(pt)
|
2018-02-26 |
2020-12-29 |
Synthorx, Inc. |
Conjugados da il-15 e usos dos mesmos
|
CN112513070A
(zh)
|
2018-02-28 |
2021-03-16 |
辉瑞公司 |
Il-15变体及其用途
|
WO2019173832A2
(en)
*
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
AU2019243580A1
(en)
|
2018-03-28 |
2020-11-12 |
Orionis Biosciences BV |
Bi-functional proteins and construction thereof
|
CU24554B1
(es)
|
2018-05-07 |
2021-11-04 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
|
CN112654635A
(zh)
*
|
2018-05-14 |
2021-04-13 |
狼人治疗公司 |
可活化细胞因子多肽及其使用方法
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
KR20210038548A
(ko)
|
2018-06-22 |
2021-04-07 |
큐진 인크. |
사이토카인-기반 생체활성 약물 및 이의 사용 방법
|
US20220106374A1
(en)
|
2018-06-22 |
2022-04-07 |
Cugene Inc |
Novel interleukin-15 (il-15) fusion proteins and uses thereof
|
CN112534052A
(zh)
|
2018-07-25 |
2021-03-19 |
奥美药业有限公司 |
全新il-21前药及使用方法
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
CA3108949A1
(en)
|
2018-08-30 |
2020-03-05 |
HCW Biologics, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
EP3870598A1
(en)
|
2018-10-23 |
2021-09-01 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
JP2022513888A
(ja)
|
2018-12-14 |
2022-02-09 |
プロヴィヴァ セラピューティクス (ホン コン) リミテッド |
Il-15組成物およびその使用方法
|
MX2021013766A
(es)
|
2019-05-14 |
2022-02-21 |
Werewolf Therapeutics Inc |
Restos de separacion y metodos de uso de los mismos.
|
EP3983432A1
(en)
|
2019-06-12 |
2022-04-20 |
Askgene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
US20220267400A1
(en)
|
2019-07-25 |
2022-08-25 |
Trutino Biosciences Inc |
Il-2 cytokine prodrugs comprising a cleavable linker
|
WO2021030483A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
WO2021035188A1
(en)
|
2019-08-21 |
2021-02-25 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
EP4021928A4
(en)
|
2019-08-29 |
2023-09-20 |
NantBio, Inc. |
MODIFIED N-810 AND ASSOCIATED METHODS
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
AU2020402097A1
(en)
|
2019-12-13 |
2022-07-07 |
Cugene Inc. |
Novel interleukin-15 (IL-15) fusion proteins and uses thereof
|
CA3164353A1
(en)
|
2019-12-13 |
2021-06-17 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
WO2021142476A1
(en)
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
US20230147832A1
(en)
|
2020-01-22 |
2023-05-11 |
City Of Hope |
Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
|
JP2023520514A
(ja)
|
2020-04-01 |
2023-05-17 |
エクシリオ デベロップメント, インコーポレイテッド |
マスク型il-15サイトカインおよびその切断産物
|
CN115734806A
(zh)
|
2020-04-01 |
2023-03-03 |
西里欧发展公司 |
掩蔽的il-12细胞因子和其切割产物
|
WO2021202675A1
(en)
|
2020-04-01 |
2021-10-07 |
Xilio Development, Inc. |
Masked il-2 cytokines and their cleavage products
|
US20230272041A1
(en)
|
2020-04-22 |
2023-08-31 |
Dragonfly Therapeutics, Inc. |
Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
|
KR20230113581A
(ko)
|
2020-11-25 |
2023-07-31 |
실리오 디벨럽먼트, 인크. |
종양 특이적 절단성 링커
|